Alisa M. Goldstein, Ph.D.

Senior Investigator

Clinical Genetics Branch

NCI/DCEG

View Site

9609 Medical Center Dr.
Room SG/6E438
Rockville, MD 20850

+1 240 276 7233

goldstea@mail.nih.gov

Research Topics

  • Identification of genetic and environmental risk factors for cancer
  • Search for high-, moderate-, and/or low-risk cancer susceptibility genes using family-based, tumor-based, and case-control/cohort studies
  • For cancers with identified major susceptibility gene mutations, investigation of other genetic and environmental factors and their interactions in the expression of disease

Biography

Dr. Goldstein received a Ph.D. in genetic epidemiology from the University of California at Los Angeles in 1988 and subsequently joined NCI. She received NIH scientific tenure in 1997. Dr. Goldstein completed a fellowship in the NIH InterInstitute Medical Genetics Program, and is board certified in medical genetics. Her research focuses on genetic epidemiologic studies of several cancers, including melanoma and upper gastrointestinal (UGI) cancer. The main goal of her studies is to understand the role of genetic and environmental factors in the etiology of these cancers. Her studies combine epidemiologic, genetic, clinical, and molecular methodologies.

Selected Publications

  1. Sargen MR, Calista D, Elder DE, Massi D, Chu EY, Potrony M, Pfeiffer RM, Carrera C, Aguilera P, Alos L, Puig S, Elenitsas R, Yang XR, Tucker MA, Landi MT, Goldstein AM. Histologic features of melanoma associated with germline mutations of CDKN2A, CDK4, and POT1 in melanoma-prone families from the United States, Italy, and Spain. J Am Acad Dermatol. 2020;83(3):860-869.
  2. Parry DM, McMaster ML, Liebsch NJ, Patronas NJ, Quezado MM, Zametkin D, Yang XR, Goldstein AM. Clinical findings in families with chordoma with and without T gene duplications and in patients with sporadic chordoma reported to the Surveillance, Epidemiology, and End Results program. J Neurosurg. 2020;134(5):1399-1408.
  3. Sargen MR, Helgadottir H, Yang XR, Harland M, Hatton JN, Jones K, Hicks BD, Hutchinson A, Curry M, Tucker MA, Goldstein AM, Pfeiffer RM. Impact of Transcript (p16/p14ARF) Alteration on Cancer Risk in CDKN2A Germline Pathogenic Variant Carriers. JNCI Cancer Spectr. 2022;6(6).
  4. Astiazaran-Symonds E, Goldstein AM. A systematic review of the prevalence of germline pathogenic variants in patients with pancreatic cancer. J Gastroenterol. 2021;56(8):713-721.
  5. Moody S, Senkin S, Islam SMA, Wang J, Nasrollahzadeh D, Cortez Cardoso Penha R, Fitzgerald S, Bergstrom EN, Atkins J, He Y, Khandekar A, Smith-Byrne K, Carreira C, Gaborieau V, Latimer C, Thomas E, Abnizova I, Bucciarelli PE, Jones D, Teague JW, Abedi-Ardekani B, Serra S, Scoazec JY, Saffar H, Azmoudeh-Ardalan F, Sotoudeh M, Nikmanesh A, Poustchi H, Niavarani A, Gharavi S, Eden M, Richman P, Campos LS, Fitzgerald RC, Ribeiro LF, Soares-Lima SC, Dzamalala C, Mmbaga BT, Shibata T, Menya D, Goldstein AM, Hu N, Malekzadeh R, Fazel A, McCormack V, McKay J, Perdomo S, Scelo G, Chanudet E, Humphreys L, Alexandrov LB, Brennan P, Stratton MR. Mutational signatures in esophageal squamous cell carcinoma from eight countries with varying incidence. Nat Genet. 2021;53(11):1553-1563.

Related Scientific Focus Areas

This page was last updated on Tuesday, November 12, 2024